Cancer patients often struggle because their immune system fails to attack tumors. New evidence suggests that activating the cGAS–STING pathway, a natural immune defense mechanism, can help fight solid tumors and blood cancers. When this pathway works well, patients show improved survival and their bodies respond better to existing immune therapies. Activating the pathway also helps immune cells mature and move into tumors to destroy them. This approach works even when combined with standard immune checkpoint inhibitors used to treat cancer.
However, the immune system is complex and can react negatively if pushed too hard. Too much activation of this pathway can cause the immune system to become exhausted or stop working properly. It can also trigger dangerous side effects that limit treatment options. This means doctors must find the right balance to get the benefits without causing harm.
Current knowledge comes mostly from lab studies and small groups of patients. We still do not know exactly which types of tumors benefit most or why some patients do not respond. More research is needed to define these limits before this strategy becomes a standard treatment for everyone.